FDA releases safety review update report for Benicar

As part of a safety review update on cardiovascular events and Benicar (olmesartan), the U.S. Food and Drug Administration states Benicar’s benefits “continue to outweigh its potential risks when used for the treatment of patients with high blood pressure according to the drug label http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=benicar&SearchType=BasicSearch. Read more at http://www.fda.gov/Drugs/DrugSafety/ucm251268.htm.

LEAVE A REPLY

Please enter your comment!
Please enter your name here